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wall and peak videointensity (PVI) was measured in gray levels. Results * =
p < 0.01 for EG vs DIP + EG.
HR FA(S) FA (D) LV PA PVI
BASE 145 ± 23 172 ± 14 120 ± 7 165 ± 12 122 ± 6 23 ± 18
EG 150 ± 24 163 ± 13 114±7 159 ± 13 28± 10 69 ± 50
DIP 142 ± 19 171 ± 14 114 ± 15 162 ± 23 24 ± 3 33 ± 21
DIP + EG 145 ± 23 156 ± 31 99 ± 21 145 ± 32 32 ± 4 110 ± 41
1. Anteroseptal
2. Anterior
3. Lateral
4. Posterolateral
5. Inferior
6. Posteroseptal
Pre-Occlusion
46.65 ± 7.01
3248 ± 1260
15.12 ± 4.39
12.13 ± 377
23.59 ± 4.62
45.21 ± 1105
Post-Occlusion
1.87 ± 2.17'
0.04 ± 5.01'
26.29 ± 843
13.43 ± 5.95
20.80 ± 9.25
19.56 ± 5.05
Reperfusion
44.17 ± 399
34.37 ± 498
5.52 ± 915
14.79 ± 455
7.58 ± 7.02
18.02 ± 410
'p < 0.001
Thus, combination of antihistamine-steriod pretreatment and dipyridamole
vasodilation enables enhanced visualization of myocardial perfusion by re-
duced doses of EG without significant hemodynamic effects. This approach
may be of value in achieving myocardial opacification in patients with EG
without incurring side effects.
As the data showed, after LAD occlusion anteroseptal (1) and anterolat-
eral (2) segments showed a statistically significant loss (*p < 0.001) of their
preocclusion contrast echo VD change and it was recovered following reper-
fusion. In our study, MRX provided visual and VD delineation of myocardium
at risk and changes induced by reperfusion after IV injection.
Thus, the ultrasound contrast agent FS069 results in measurable, con-
sistent, and reproducible myocardial opacification when administered intra-
venously.
Howard C. Dittrich, Gary L. Bales, Britta A McFerran, Mary T. Kuvelas, Roberta
M. Hunt. Yigal Greener University of California, San Diego, CA; Molecular Biosysterns,
Inc. San Diego, CA
In order for myocardial contrast echocardiography to become clinically use-
ful, ultrasound contrast agents must result in reproducible opacification. We
therefore studied a new agent capable of producing myocardial opacification
when given intravenously. FS069, proteinaceous, gas-filled microspheres
(mean size range: 3.6-5.4 micron, concentration: 6.3-9.0 x 108/m11. was
administered to 10 closed-chest anesthetized dogs (20-29 kgl in doses of
0.4--0.7 ml at a rate of 0.3 mllsec into an internal jugular or cephalic vein.
Total volumes/dog were 28-54 ml. Transthoracic, parasternal short axis im-
ages were acquired using a Hewlett Packard Sonos 1500 and time-intensity
curves from gated images were generated from the anterior, septal, and lat-
eral left ventricular walls and cavity with an on-line system. The increase in
mean pixel intensity compared to baseline was measured. No changes in
heart rate, systemic blood pressure, or arterial blood gases attributable to
FS069 were detected. Myocardial opacification in multiple segments was
documented in 100% of injections. There was no significant difference in in-
tensity change between injections although there was a difference between
myocardial segments within the same injection.
Reproducibility of Myocardial Opacification Using
FS069, a New Intravenously Administered
Ultrasound Contrast Agent
24± 8
14 ± 6'
ATT
0.6 ± 0.9
34 ± 24'
PWPMVI
Intravenous Dextrose Albumin Sonicated with
Evaporated Pertluoropentane Reduces Left
Ventricular CaVity Attenuation and Improves the
Echocardiographic Detection of Posterior
Myocardial Pertusion Abnormalities
4.8 ± 2.2
44± 1.5
AWPMVI
PESDA
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'p < 0.01 compared to PESDA
Thomas Porter, Feng Xie, Alan Kricsfeld. University ofNebraska Medical Centerm,
Omaha, Nebraska
Large concentrations of intravenous (IV) albumin microbubbles are capable
of producing visual anterior myocardial contrast (MC). This also results in
high left ventricular cavity contrast which prevents visualization of posterior
myocardium due to attenuation. Recently, MC following intravenous soni-
cated dextrose albumin has been possible by altering microbubble (MB) gas
composition to one with lower blood solubility and diffusivity due to their
higher molecular weight (MW). Since this preserves MB size in blood, we hy-
pothesized that lower doses of this contrast could produce the same MC ef-
fect with less cavity attenuation following intravenous injection. Accordingly,
we sonicated dextrose albumin with two different gases of different MW:
an evaporated fluorocarbon gas (perfluoropentane: MW 270 grams/mole
(PPSDA); or perfluoropropane MW 188 g/mole (PESDA)). A total of 30 intra-
venous doses of 0.015-0.060 mllkg of the two different samples were given
to open chest dogs under baseline conditions, during adenosine infusion
(140Ikg/min), during acute ischemia produced by a left circumflex stenosis
or occlusion, and finally during subsequent reperfusion of the circumflex ves-
sel. The peak myocardial videointensity (PMVI) and duration (in seconds) of
attenuation (AD) in the posterior wall of these two agents were compared.
PMVI in the anterior (AW) and posterior wall (PW) were measured following
each injection, as were left circumflex and left anterior descending flow rates
with a Transonic Doppler. Values are mean ± standard deviation:
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Cavity
16.8 ± 66
16.4±7.0
0.99"
2.2 ± 15
2.1 ± 2.4
0.86'
Lateral
05 ± 0.6 52 ± 4.6
0.5 ± 0.6 4.9 ± 4.5
0.48 0.94"
Anterior Septal
Intensity Change (mean ± SD)
Injection 1, dB
Injection 2, dB
1 vs. 2, r
, < 0.01," < 0001
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Jinping Xu, George A Pantely, Shuping Ge, Susan Grauer, Takahiro Shiota,
Zheng Gong, Xiaodong Zhou, David J. Sahn. Oregon Health Sciences University,
Portland, Oregon
The availability of new contrast agents capable of transpulmonary, left ven-
tricular and myocardial opacification after intravenous injection warrants
evaluation of their efficacy for assessing abnormalities of myocardium per-
fusion and results of intervention. In the present study, open chest epicardial
echocardiography(7 MHz)was performed during intravenous administration
of MRX 115, a new lipid contrast agent at a dose of 0.02 or 0.05 mllkg in 6
instrumented monkeys before and after acute LAD ligation and following
reperfusion. Visually apparent myocardial opacification was evident in all an-
imals for all IV injections of MRX before LAD occlusion without significant
hemodynamic effect. After LAD occlusion, a "filling defect" overlapping the
area with abnormal wall motion could be delineated and uptake of subse-
quently injected contrast could be demonstrated within 10 to 20 minutes fol-
lowing release of LAD occlusion. The peak videodensitometric (VD) changes
(256 unit scale) from baseline after IV MRX injection over each of 6 areas of
coronary perfusion areas on the LV short axis before and after LAD occlusion
and 20 minutes following release are shown (mean ± SE):
IV PPSDABaseline
Both agents produced visua/Iy evident and similar anterior myocardial con-
trast, but PESDA caused prolonged posterior wall attenuation and failed to
produce significant posterior wall contrast. The dextrose albumin sonicated
with the gas of highest MW (PPSDA) produced significantly higher posterior
wall contrast (see example) which also improved the detection of area at risk
during LCX ischemia. We conclude that dextrose albumin sonicated with an
evaporated larger molecular weight fluorocarbon gas results in (a) improved
myocardial contrast of the posterior leftventricularwall with significantly less
attenuation; and (b) visual determination of the area at risk during posterior
ischemia.
Intracardiac Echocardiographic Quantification
and Monitoring of Myocardial Perfusion Defects
and Repertusion with the Use of Intravenous
Injection of FS069, a Transpulmonic Contrast
Agent
Steven Schwartz, Oi-Ling Cao, Alain Delabays, Lissa Sugeng, Natesa Pandian.
Tufts-New England Medical Cente" Boston, Massachusetts
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Contrast Echocardiographic Assessment of
Myocardial Pertusion Following Acute Coronary
Artery Occlusion and Repertusion Using
Intravenous Injection of Aerosome,. MRX 115 in
Monkeys
1955-561
Despite major efforts, echocardiographic delineation of LV myocardial hy-
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Advanced Age is not a Contraindication for
Primary Infarct Angioplasty in Patients with
Cardiogenic Shock
The degree of reperfusion achieved following intravenous (IV) thrombolysis
is an important factor in patient prognosis. and rapid non-invasive identifica-
tion of this in the management of acute myocardial infarction is essential.
Recently. IV sonicated dextrose albumin (SDA) perfused with a gas of low
blood solubility and diffusivity (perfluoropropane (PF)) has been capable of
producing myocardial contrast following IV injection which correlates closely
with coronary blood flow (CBF). We hypothesized that this agent could de-
tect the amount of CBF following coronary reperfusion. Accordingly. we gave
a standard dose (0.06 mllkg) of IV PF-enhanced SDA (PESDA) in seven dogs
at baseline. during acute ischemia produced by a 100% left circumflex (LCX)
ligature, and during reperfusion (REP) but with quantitative angiographic (au-
tomated border detection) evidence of a residual stenosis (RS) varying from
19 to 90% in diameter. The background-subtracted peak myocardial videoin-
tensity (PMVI) produced by IV PESDA was measured in the LCX and left
anterior descending (LAD) perfusion beds. and correlated with actual flow
(CBF) using a Doppler flow cuff over the LCX and LAD. as well as RS sever-
ity by quantitative angiography (OA). Wall thickening (WT) responses were
also measured as the difference in LCX perfusion bed end-diastolic and end-
systolic wall thickness. The presence of infarction was documented with
triphenyl tetrazolium chloride (TIC) staining.
The range of Doppler flows in the LCX following reperfusion was 8-50
mllmin. There was a strong correlation (r = 0.85. p < 0.001) between resid-
ual LCX CBF after REP with a RS and PMVI in the LCX perfusion bed. Failure
of PMVI to return to baseline PMVI following REP was seen only in dogs
who had a greater than 80% RS. The correlation between PMVI and LCX
flow remained good when the RS was removed except where there was
TIC evidence of infarction. There was also a correlation between RS sever-
ity by QA and LCX PMVI (r = 0.63; P = 0.002). In contrast. WT correlated
poorly with LCX flow following REP (r = 0.44). These data indicate that PMVI
following intravenous PESDA can detect residual coronary blood flow ab-
normalities following REP of a totally occluded coronary artery. This agent.
therefore. could potentially be used in humans to non-invasively determine
the degree of coronary blood flow achieved following reperfusion therapy in
acute myocardial infarction.
Echocardiographic Detection of Residual
Coronary Flow Abnormalities and Stenosis
Severity After Coronary Reperfusion Using
Intravenous Perfluoropropane-enhanced
Sonicated Dextrose Albumin
Thomas Porter. Feng Xie. Karen Kilzer. Alan Kricsfeld. Ubeydullah Deligonul.
University ofNebraska Medical Center, Omaha. Nebraska
Direct PTCA and Thrombolytic Therapy for
Acute Myocardial Infarction
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Patients with cardiogenic shock during acute myocardial infarction have high
mortality. It has been suggested that survival rates approach zero in those
patients over age 75. and therefore intervention is contraindicated. We re-
port a retrospective review of 97 patients presenting with cardiogenic shock
during acute infarction with analysis based on patient age. Acute infarction
was defined by standard ECG criteria. Cardiogenic shock was defined by sys-
tolic pressure <80 mmHg with evidence of systemic hypoperfusion in the
presence of adequate filling pressures.
The groups were similar in respect to infarct location. number of dis-
eased arteries. prior CABG, and diabetes; there was a greater percentage
of women in the elderly group vs. the younger group (61.5% vs. 31.0%. p =
0.01). Results of therapy are as follows:
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poperfusion with intravenously (IV) injected contrast remains difficult be-
cause of the lack of an ideal agent. and problems in resolution of transtho-
racic 2DE images. In this study, we explored the potential of 2 new ap-
proaches: 1) a new IV contrast agent, FS069 (MBI) that can cross the pul-
monary circulation and 2) Intracardiac echocardiography (ICE) that can de-
pict LV myocardium crisply. In 5 anesthetized dogs. ICE was performed us-
ing a 6 Fr. 12.5 MHz catheter within the LV Once short-axis views were ob-
tained. a small dose (0.3 mg) of FS069 was injected into the femoral vein
at baseline. following occlusion of the LAD. PDA, and OM coronary arteries,
and after reperfusion. Continuous ICE monitoring was performed. Perfusion
defects. quantified and expressed as % of LV, were correlated with the ex-
tent of regional wall motion abnormalities (WMA) measured in ICE images
without contrast. Results: After IV injection, the RV cavity was opacified, fol-
lowed by the LV cavity. All endocardial borders were well defined. Contrast
enhancement was noted within the myocardium within 5 beats of LV cavity
opacification. During 18 episodes of ischemia we produced. opacification of
the LV cavity facilitated identification of WMA in all. Perfusion defects corre-
sponding to WMAs were observed in all cases where WMAs were present;
however 2 episodes of ischemia were not accompanied by either contrast
defects or WMA. Defects were visible long enough for ICE to image the LV
at multiple levels. Following reperfusion and re-injection of contrast. no de-
fects were noted. The perfusion defects ranged from 13-62% (mean 37.6
± 14.8) of the total LV; the extent of WMA was 14-66% (mean 39.0 ± 15.2)
of the LV circumference. Defect size (x) correlated well with extent of WMA
Iy), with y = 0.98x + 2.1. r = 0.95. P < 0.001. Conclusion: (1) IV injection
of FS069 is sensitive and strong enough to demonstrate myocardial perfu-
sion and ischemia that can be quantified by ICE; (2) Contrast changes persist
long enough to image all levels of the LV by ICE; (3) Catheter-based imaging,
when refined. could be useful for monitoring ischemia and perfusion status.
Harmonic Contrast Echocardiography: A New
Method for Detecting Myocardial Opacification
After Intravenous Injection of Contrast
Kunio Miyatake. Masaaki Uematsu, Hisao Matsuda. Masakazu Yamagishi.
Seiki Nagata. Shintaro Beppu. Yoshitaka Mine. Naohisa Kamiyama. Makoto Hirama.
National Cardiovascular Center, Osaka. Japan; Toshiba Corp., Tochigi, Japan
Detection of myocardial opacification after intravenous injection of contrast
is of great diagnostic value. To achieve this goal. we applied harmonic imag-
ing to myocardial contrast echocardiography. Contrast agents emit strong
harmonics at double the frequency of transmitted ultrasound. while the tis-
sue does not. Thus. harmonic imaging improves the tissue-agent contrast.
We used a prototype phased-array harmonic echocardiographic system with
a sector probe that transmits ultrasound at 2.5 MHz and receives at 5 MHz
(Toshiba Corp.). SHU-508 (Schering). a galactose-based contrast agent, was
injected through femoral vein (0.13-0.24 mllkg; 400 mg/ml) in 5 anesthetized
open chest dogs. Images were recorded on videotapes and subsequently
analyzed with a Quadra 840AV (Apple) based microcomputer system. Time-
intensity plots were generated in the end-diastolic images by setting the re-
gion of interest to the anterior LV wall. In 3 dogs. shortly after the opacifi-
cation in LV lumen, the intensity in the myocardium increased and gradually
declined to the basal level as shown in the figure. No significant hemody-
namic alterations were noted with these doses of SHU-50S. Thus, success-
ful myocardial opacification can be achieved during harmonic imaging after
intravenous injection of contrast. Harmonic contrast echocardiography is a
feasible. promising technique to detect myocardial perfusion.
(dB)
LV opacification
..
Subgroup Procedural success In hospital mortality
Age < 70(n = 71)
Age", 70(n ~ 26)
80.3%,
84.6%.
P = 0.84
42.3%.
53.8%.
P = 0.43
The occurrence of urgent CABG and stroke was similar between groups.
Mortality remained comparable between age groups regardless of proce-
dural success or failure. Using multivariate analysis, infarct location (anterior
